Paper Details

  1. Home
  2. Paper Details

A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.

Author: BallardClive, BanerjeeSube, BenthamPeter, BurnsAlistair, FarinaNicolas, FountainJulia, FoxChris, FrancisPaul, HendersonCatherine, HighJuliet, HowardRobert, KnappMartin, LeroiIracema, LivingstonGill, NilforooshanRamin, NurockShirley, O'BrienJohn, PriceAnnabel, ShepstoneLee, StirlingSusan, SwartAnn Marie, TabetNaji, TellingTanya, ThomasAlan J

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Pragmatic Clinical TrialA trial conducted in a real-world clinical setting. It evaluates the effectiveness of interventions in everyday healthcare environments.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A clinical trial of mirtazapine for agitation in dementia found that it was not clinically or cost-effective compared to placebo. Therefore, there is no reason to recommend mirtazapine for people with dementia who have agitation.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Agitation is common and impacts negatively on people with dementia and carers. Non-drug patient-centred care is first-line treatment, but we need other treatment when this fails. Current evidence is sparse on safer and effective alternatives to antipsychotics. OBJECTIVES: To assess clin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641860/

データ提供：米国国立医学図書館（NLM）

Agitation in Alzheimer's Disease: A Desert of Challenges

This research explores the effectiveness of mirtazapine and carbamazepine, two medications, in managing agitation in individuals with Alzheimer's disease. The study, utilizing a [pragmatic, multicenter, double-blind, placebo-controlled] design, aimed to assess the clinical effectiveness and safety of these medications. The authors found that mirtazapine did not demonstrate significant benefits in reducing agitation compared to placebo. This finding highlights the ongoing challenges in finding effective treatments for agitation in Alzheimer's disease.

Navigating Agitation: A Challenging Path

This study underscores the complexities of managing agitation in individuals with Alzheimer's disease. The lack of significant benefits observed with mirtazapine reinforces the need for further research and development of effective treatment strategies. Understanding the underlying causes of agitation in Alzheimer's disease and exploring alternative therapeutic approaches are crucial for improving patient care.

Agitation in Alzheimer's Disease: A Desolate Landscape

Agitation in Alzheimer's disease can be a significant challenge for both patients and caregivers. This research highlights the difficulty in finding effective treatments. It's important to seek professional guidance and support to navigate this challenging condition. Just as a camel endures harsh desert conditions, caregivers must be prepared to face the challenges associated with agitation in Alzheimer's disease.

Dr. Camel's Conclusion

This research underscores the complexities of managing agitation in Alzheimer's disease, emphasizing the need for continued research and exploration of alternative treatment approaches. Just as a camel navigates a vast and unforgiving desert, finding effective treatments for agitation in Alzheimer's disease requires perseverance, understanding, and a commitment to improving patient care.

Date :
  1. Date Completed 2023-11-08
  2. Date Revised 2023-11-15
Further Info :

Pubmed ID

37929672

DOI: Digital Object Identifier

PMC10641860

Related Literature

Article Analysis
・Effective treatment of dementia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.